This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bédos, J.-P.
Right arrow Articles by Azoulay-Dupuis, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bédos, J.-P.
Right arrow Articles by Azoulay-Dupuis, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 1998, p. 862-867, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Efficacy of Trovafloxacin against Penicillin-Susceptible and Multiresistant Strains of Streptococcus pneumoniae in a Mouse Pneumonia Model

Jean-Pierre Bédos, Véronique Rieux, Jacqueline Bauchet, Martine Muffat-Joly, Claude Carbon, and Esther Azoulay-Dupuis*

Institut National de la Santé et de la Recherche Médicale, Unité 13, Hôpital Bichat-Claude Bernard, 75877 Paris Cedex 18, France

Received 7 August 1997/Returned for modification 21 October 1997/Accepted 5 February 1998

The increasing emergence of penicillin-resistant and multidrug-resistant strains of Streptococcus pneumoniae will create a serious therapeutic problem in coming years. Trovafloxacin is a novel naphthyridone quinolone with promising activity against S. pneumoniae, including penicillin-resistant strains (MIC for 90% of the isolates tested, 0.25 µg/ml). We compared its in vivo efficacy with that of other fluoroquinolones (ciprofloxacin, temafloxacin, and sparfloxacin) and a reference beta-lactam (amoxicillin) in a model of acute experimental pneumonia. Immunocompetent Swiss mice were infected by peroral tracheal delivery of a virulent, penicillin-susceptible strain (MIC, 0.03 µg/ml); leukopenic Swiss mice were infected with three poorly virulent, penicillin-resistant strains (MICs, 4 to 8 µg/ml) and a ciprofloxacin-resistant strain (MIC, 32 µg/ml). Treatments were started 6 h (immunocompetent mice) or 3 h (leukopenic mice) after infection. Doses ranging from 12.5 to 300 mg/kg were given at 12- or 8-h intervals for 3 days. Trovafloxacin (25 mg/kg) was the most effective agent in vivo against penicillin-susceptible and -resistant strains. Corresponding survival rates were 2- to 4-fold higher than with 50-mg/kg sparfloxacin or temafloxacin and 8- to 16-fold higher than with 100-mg/kg ciprofloxacin. The ratios of the area under the concentration-time curve to the MIC in serum and lung tissue were more favorable with trovafloxacin than with the other quinolones. Efficacy in vivo correlated with pharmacokinetic parameters. Trovafloxacin shows potential for the treatment of infections due to penicillin-susceptible and -resistant S. pneumoniae but appears to be ineffective against a ciprofloxacin-resistant strain.

* Corresponding author. Mailing address: Institut National de la Santé et de la Recherche Médicale, Unité 13, Hôpital Bichat-Claude Bernard, 170 Bd Ney, 75877 Paris Cedex 18, France. Phone: 33 (0)1 40 25 86 08. Fax: 33 (0)1 40 25 86 02. E-mail: u13bcb{at}magic.fr.

Antimicrobial Agents and Chemotherapy, April 1998, p. 862-867, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Chiavolini, D., Pozzi, G., Ricci, S. (2008). Animal Models of Streptococcus pneumoniae Disease. Clin. Microbiol. Rev. 21: 666-685 [Abstract] [Full Text]  
  • Azoulay-Dupuis, E., Bedos, J. P., Mohler, J., Moine, P., Cherbuliez, C., Peytavin, G., Fantin, B., Kohler, T. (2005). Activity of Gemifloxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model. Antimicrob. Agents Chemother. 49: 1046-1054 [Abstract] [Full Text]  
  • Bast, D. J., Yue, M., Chen, X., Bell, D., Dresser, L., Saskin, R., Mandell, L. A., Low, D. E., de Azavedo, J. C. S. (2004). Novel Murine Model of Pneumococcal Pneumonia: Use of Temperature as a Measure of Disease Severity To Compare the Efficacies of Moxifloxacin and Levofloxacin. Antimicrob. Agents Chemother. 48: 3343-3348 [Abstract] [Full Text]  
  • Azoulay-Dupuis, E., Bedos, J. P., Mohler, J., Peytavin, G., Isturiz, R., Moine, P., Rieux, V., Cherbuliez, C., Pechere, J. C., Fantin, B., Kohler, T. (2004). Activities of Garenoxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model. Antimicrob. Agents Chemother. 48: 765-773 [Abstract] [Full Text]  
  • Scaglione, F., Mouton, J. W., Mattina, R., Fraschini, F. (2003). Pharmacodynamics of Levofloxacin and Ciprofloxacin in a Murine Pneumonia Model: Peak Concentration/MIC versus Area under the Curve/MIC Ratios. Antimicrob. Agents Chemother. 47: 2749-2755 [Abstract] [Full Text]  
  • Inoue, S., Nakamura, H., Otake, K., Saito, H., Terashita, K., Sato, J., Takeda, H., Tomoike, H. (2003). Impaired Pulmonary Inflammatory Responses Are a Prominent Feature of Streptococcal Pneumonia in Mice with Experimental Emphysema. Am. J. Respir. Crit. Care Med. 167: 764-770 [Abstract] [Full Text]  
  • Coyle, E. A., Kaatz, G. W., Rybak, M. J. (2001). Activities of Newer Fluoroquinolones against Ciprofloxacin-Resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 1654-1659 [Abstract] [Full Text]  
  • Fornas, F. L., Garcia, F. M., Salmeron, J. P., Conesa, D. R., Sanchez, R. C., Alberola, A. G., Gomez, J. R., Gomez, J. G., Chavarri, M. V. (2001). Comparative study of treatment with penicillin, ceftriaxone, trovafloxacin, quinupristin-dalfopristin and vancomycin in experimental endocarditis due to penicillin- and ceftriaxone-resistant Streptococcus pneumoniae. J Antimicrob Chemother 47: 623-629 [Abstract] [Full Text]  
  • Hershberger, E., Rybak, M. J. (2000). Activities of Trovafloxacin, Gatifloxacin, Clinafloxacin, Sparfloxacin, Levofloxacin, and Ciprofloxacin against Penicillin-Resistant Streptococcus pneumoniae in an In Vitro Infection Model. Antimicrob. Agents Chemother. 44: 598-601 [Abstract] [Full Text]  
  • Thadepalli, H., Reddy, U., Chuah, S. K., Hanna, N., Rana, G., Gollapudi, S. (2000). Evaluation of trovafloxacin in the treatment of Klebsiella pneumoniae lung infection in tumour-bearing mice. J Antimicrob Chemother 45: 69-75 [Abstract] [Full Text]  
  • Ng, W., Lutsar, I., Wubbel, L., Ghaffar, F., Jafri, H., McCracken, G. H., Friedland, I. R. (1999). Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia. J Antimicrob Chemother 43: 811-816 [Abstract] [Full Text]  
  • Jorgensen, J. H., Weigel, L. M., Ferraro, M. J., Swenson, J. M., Tenover, F. C. (1999). Activities of Newer Fluoroquinolones against Streptococcus pneumoniae Clinical Isolates Including Those with Mutations in the gyrA, parC, and parE Loci. Antimicrob. Agents Chemother. 43: 329-334 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»